BridgeBio Pharma, Inc. (BBIO)
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months
BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby's U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO's $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline investment.
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.
BridgeBio Pharma Q2 Earnings Call Highlights
BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year.
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market.
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
